Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|14|2164-2173

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.14, 2014-07, pp. : 2164-2173

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Single-Nucleotide Polymorphisms in the Vascular Endothelial Growth Factor Pathway and Outcomes of Patients Treated with First-Line Cytotoxic Chemotherapy Combined with Bevacizumab for Advanced Colorectal Cancer

By  

Oncology, Vol. 87, Iss. 5, 2014-08 ,pp. : 280-292

Karger

Access to resources Recommend Favorite

Phase I Study of Two Schedules of Oral S-1 in Combination with Fixed Doses of Oxaliplatin and Bevacizumab in Patients with Advanced Solid Tumors

By  

Oncology, Vol. 81, Iss. 2, 2011-09 ,pp. : 65-72

Karger

Access to resources Recommend Favorite

Clinicopathologic Significance of Nuclear Factor-κB and Vascular Endothelial Growth Factor Expression in Advanced Gastric Cancer Patients

By  

Oncology Research and Treatment, Vol. 37, Iss. 4, 2014-03 ,pp. : 183-190

Karger

Access to resources Recommend Favorite

A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma

By  

CANCER, Vol. 121, Iss. 19, 2015-10 ,pp. : 3481-3490

John Wiley & Sons Inc

Access to resources Recommend Favorite

Inhibition of Thrombin-Induced Vascular Endothelial Growth Factor Production in Human Neuroblastoma (NB-1) Cells by Argatroban

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 34, Iss. 1, 2005-11 ,pp. : 41-47

Karger

Access to resources Recommend Favorite